The project
Targeted Humoral and Cellular Therapy for Childhood, Adolescent and Young Adult Classical Hodgkin Lymphoma
PCF's published Our Impact description, checked September 15, 2026. Planned trial, enrollment and site language below is source wording, not a current trial-status update.
This project tests antibody-based therapies with reduced-toxicity chemotherapy and develops gene-edited immune cell treatments to improve outcomes and reduce long-term harm for children and young adults with classical Hodgkin Lymphoma.